Emerging Targets in Anti-Tubercular Drug Design

Keith D. Green; Selina Y.L. Holbrook; Huy X. Ngo; Sylvie Garneau-Tsodikova

doi:10.1039/9781782629870-00141

Emerging Targets in Anti-Tubercular Drug Design

Keith D. Green, Selina Y.L. Holbrook, Huy X. Ngo, Sylvie Garneau-Tsodikova

Pharmaceutical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Scopus citations

Abstract

Tuberculosis (TB) is currently the second most lethal infection following HIV. In 2014 alone, there were 9.6 million new cases of TB and 1.5 million TB-related deaths reported worldwide. It is also estimated that about one third of the entire population carries latent Mycobacterium tuberculosis (Mtb), the etiological cause of TB. These individuals are asymptomatic, but can develop a full TB infection if left untreated. The current first-line TB treatment consists of a cocktail of isoniazid, rifampicin, pyrazinamide, and ethambutol. A fraction of Mtb strains develop resistance to isoniazid and rifampicin and are usually treated with second-line anti-tubercular agents, such as aminoglycosides, fluoroquinolones, or the antimicrobial peptide capreomycin. Some strains acquire further resistance to second-line treatments, causing a significantly higher mortality rate. The increase of drug-resistant Mtb strains has triggered action in the scientific field, which has led to a renaissance in anti-tubercular drug discovery with multiple emerging drug targets. Herein, we summarize the latest enzymes, pathways, and mechanisms presented in the literature (covering 2000-2016) related to the emergence of promising targets in anti-tubercular drug design.

Original language	English
Title of host publication	Allosterism in Drug Discovery
Editors	David Thurston, Troy Lister, Steven M. Firestine
Pages	141-203
Number of pages	63
Edition	58
DOIs	https://doi.org/10.1039/9781782629870-00141
State	Published - 2017

Publication series

Name	RSC Drug Discovery Series
Number	58
Volume	2017-January
ISSN (Print)	2041-3203
ISSN (Electronic)	2041-3211

Bibliographical note

Funding Information:
The author is grateful to Gwenola Auda-Boucher and Yvonnick Cheraud for their collaboration during this research, Martine Molina for typing the manuscript, Felix Crossin for contributing photographic materials, Thierry Rouaud and Maryvonne Zampieri for their technical assistance, and Dr. James Gray for reading the manuscript. This work was supported by the University of Nantes, the Centre National de la Recherche Scientifique, and the Association Franeaise contre les Myopathies.

Publisher Copyright:
© The Royal Society of Chemistry 2017.

ASJC Scopus subject areas

Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/9781782629870-00141

Cite this

@inbook{0213bfec83a642c883a15b9017c19491,

title = "Emerging Targets in Anti-Tubercular Drug Design",

abstract = "Tuberculosis (TB) is currently the second most lethal infection following HIV. In 2014 alone, there were 9.6 million new cases of TB and 1.5 million TB-related deaths reported worldwide. It is also estimated that about one third of the entire population carries latent Mycobacterium tuberculosis (Mtb), the etiological cause of TB. These individuals are asymptomatic, but can develop a full TB infection if left untreated. The current first-line TB treatment consists of a cocktail of isoniazid, rifampicin, pyrazinamide, and ethambutol. A fraction of Mtb strains develop resistance to isoniazid and rifampicin and are usually treated with second-line anti-tubercular agents, such as aminoglycosides, fluoroquinolones, or the antimicrobial peptide capreomycin. Some strains acquire further resistance to second-line treatments, causing a significantly higher mortality rate. The increase of drug-resistant Mtb strains has triggered action in the scientific field, which has led to a renaissance in anti-tubercular drug discovery with multiple emerging drug targets. Herein, we summarize the latest enzymes, pathways, and mechanisms presented in the literature (covering 2000-2016) related to the emergence of promising targets in anti-tubercular drug design.",

author = "Green, {Keith D.} and Holbrook, {Selina Y.L.} and Ngo, {Huy X.} and Sylvie Garneau-Tsodikova",

note = "Funding Information: The author is grateful to Gwenola Auda-Boucher and Yvonnick Cheraud for their collaboration during this research, Martine Molina for typing the manuscript, Felix Crossin for contributing photographic materials, Thierry Rouaud and Maryvonne Zampieri for their technical assistance, and Dr. James Gray for reading the manuscript. This work was supported by the University of Nantes, the Centre National de la Recherche Scientifique, and the Association Franeaise contre les Myopathies. Publisher Copyright: {\textcopyright} The Royal Society of Chemistry 2017.",

year = "2017",

doi = "10.1039/9781782629870-00141",

language = "English",

series = "RSC Drug Discovery Series",

number = "58",

pages = "141--203",

editor = "David Thurston and Troy Lister and Firestine, {Steven M.}",

booktitle = "Allosterism in Drug Discovery",

edition = "58",

}

TY - CHAP

T1 - Emerging Targets in Anti-Tubercular Drug Design

AU - Green, Keith D.

AU - Holbrook, Selina Y.L.

AU - Ngo, Huy X.

AU - Garneau-Tsodikova, Sylvie

N1 - Funding Information: The author is grateful to Gwenola Auda-Boucher and Yvonnick Cheraud for their collaboration during this research, Martine Molina for typing the manuscript, Felix Crossin for contributing photographic materials, Thierry Rouaud and Maryvonne Zampieri for their technical assistance, and Dr. James Gray for reading the manuscript. This work was supported by the University of Nantes, the Centre National de la Recherche Scientifique, and the Association Franeaise contre les Myopathies. Publisher Copyright: © The Royal Society of Chemistry 2017.

PY - 2017

Y1 - 2017

N2 - Tuberculosis (TB) is currently the second most lethal infection following HIV. In 2014 alone, there were 9.6 million new cases of TB and 1.5 million TB-related deaths reported worldwide. It is also estimated that about one third of the entire population carries latent Mycobacterium tuberculosis (Mtb), the etiological cause of TB. These individuals are asymptomatic, but can develop a full TB infection if left untreated. The current first-line TB treatment consists of a cocktail of isoniazid, rifampicin, pyrazinamide, and ethambutol. A fraction of Mtb strains develop resistance to isoniazid and rifampicin and are usually treated with second-line anti-tubercular agents, such as aminoglycosides, fluoroquinolones, or the antimicrobial peptide capreomycin. Some strains acquire further resistance to second-line treatments, causing a significantly higher mortality rate. The increase of drug-resistant Mtb strains has triggered action in the scientific field, which has led to a renaissance in anti-tubercular drug discovery with multiple emerging drug targets. Herein, we summarize the latest enzymes, pathways, and mechanisms presented in the literature (covering 2000-2016) related to the emergence of promising targets in anti-tubercular drug design.

AB - Tuberculosis (TB) is currently the second most lethal infection following HIV. In 2014 alone, there were 9.6 million new cases of TB and 1.5 million TB-related deaths reported worldwide. It is also estimated that about one third of the entire population carries latent Mycobacterium tuberculosis (Mtb), the etiological cause of TB. These individuals are asymptomatic, but can develop a full TB infection if left untreated. The current first-line TB treatment consists of a cocktail of isoniazid, rifampicin, pyrazinamide, and ethambutol. A fraction of Mtb strains develop resistance to isoniazid and rifampicin and are usually treated with second-line anti-tubercular agents, such as aminoglycosides, fluoroquinolones, or the antimicrobial peptide capreomycin. Some strains acquire further resistance to second-line treatments, causing a significantly higher mortality rate. The increase of drug-resistant Mtb strains has triggered action in the scientific field, which has led to a renaissance in anti-tubercular drug discovery with multiple emerging drug targets. Herein, we summarize the latest enzymes, pathways, and mechanisms presented in the literature (covering 2000-2016) related to the emergence of promising targets in anti-tubercular drug design.

UR - http://www.scopus.com/inward/record.url?scp=85020429053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020429053&partnerID=8YFLogxK

U2 - 10.1039/9781782629870-00141

DO - 10.1039/9781782629870-00141

M3 - Chapter

AN - SCOPUS:85020429053

T3 - RSC Drug Discovery Series

SP - 141

EP - 203

BT - Allosterism in Drug Discovery

A2 - Thurston, David

A2 - Lister, Troy

A2 - Firestine, Steven M.

ER -

Emerging Targets in Anti-Tubercular Drug Design

Abstract

Publication series

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this